Market news

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. See why VIR stock is a buy.

Vir Biotechnology (VIR) stock jumps after Q2 earnings beat and Astellas deal boosts cash to $1B; preview ECLIPSE catalysts and key levels—read now.

Motley Fool Press Release.

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SAN FRANCISCO, August 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026.

Vir Biotechnology (VIR) stock is in focus after Chief Financial Officer Jason O’Byrne decided to step down effective August 3, 2026, with senior finance executive Brent Sabatini appointed as the interim principal financial officer. See our latest analysis for Vir Biotechnology. Recent trading reflects this leadership change coming at a time when Vir Biotechnology’s 30 day share price return is down 9.41% and its 90 day share price return is down 13.40%. This is despite a year to date share...

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

SAN FRANCISCO, July 24, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.

SAN FRANCISCO, July 22, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.